nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Ischaemia—Sorafenib—liver cancer	0.0489	0.0537	CcSEcCtD
Regadenoson—S-Adenosylmethionine—GNMT—liver cancer	0.0411	0.461	CrCbGaD
Regadenoson—Transient ischaemic attack—Sorafenib—liver cancer	0.0353	0.0388	CcSEcCtD
Regadenoson—Electrocardiogram ST segment depression—Epirubicin—liver cancer	0.029	0.0319	CcSEcCtD
Regadenoson—Respiratory distress—Sorafenib—liver cancer	0.0281	0.0308	CcSEcCtD
Regadenoson—Electrocardiogram ST segment depression—Doxorubicin—liver cancer	0.0269	0.0295	CcSEcCtD
Regadenoson—Adenosine triphosphate—TNK2—liver cancer	0.0254	0.285	CrCbGaD
Regadenoson—Myocardial ischaemia—Sorafenib—liver cancer	0.0222	0.0244	CcSEcCtD
Regadenoson—Pain in extremity—Sorafenib—liver cancer	0.0129	0.0142	CcSEcCtD
Regadenoson—Abdominal discomfort—Sorafenib—liver cancer	0.0107	0.0118	CcSEcCtD
Regadenoson—Acute coronary syndrome—Sorafenib—liver cancer	0.00983	0.0108	CcSEcCtD
Regadenoson—Renal failure—Sorafenib—liver cancer	0.00981	0.0108	CcSEcCtD
Regadenoson—Myocardial infarction—Sorafenib—liver cancer	0.00978	0.0107	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—liver cancer	0.00911	0.102	CrCbGaD
Regadenoson—Ventricular arrhythmia—Epirubicin—liver cancer	0.0089	0.00978	CcSEcCtD
Regadenoson—Connective tissue disorder—Sorafenib—liver cancer	0.0088	0.00966	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABL1—liver cancer	0.0086	0.0965	CrCbGaD
Regadenoson—Feeling hot—Epirubicin—liver cancer	0.0084	0.00922	CcSEcCtD
Regadenoson—Tinnitus—Sorafenib—liver cancer	0.00835	0.00917	CcSEcCtD
Regadenoson—Flushing—Sorafenib—liver cancer	0.00831	0.00912	CcSEcCtD
Regadenoson—Cardiac disorder—Sorafenib—liver cancer	0.00831	0.00912	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00824	0.00904	CcSEcCtD
Regadenoson—Angiopathy—Sorafenib—liver cancer	0.00812	0.00892	CcSEcCtD
Regadenoson—Immune system disorder—Sorafenib—liver cancer	0.00809	0.00888	CcSEcCtD
Regadenoson—Injection site pain—Epirubicin—liver cancer	0.00807	0.00886	CcSEcCtD
Regadenoson—Mediastinal disorder—Sorafenib—liver cancer	0.00807	0.00886	CcSEcCtD
Regadenoson—Mental disorder—Sorafenib—liver cancer	0.00785	0.00861	CcSEcCtD
Regadenoson—Erythema—Sorafenib—liver cancer	0.0078	0.00856	CcSEcCtD
Regadenoson—Feeling hot—Doxorubicin—liver cancer	0.00777	0.00853	CcSEcCtD
Regadenoson—Dysgeusia—Sorafenib—liver cancer	0.00763	0.00838	CcSEcCtD
Regadenoson—Vasodilation—Epirubicin—liver cancer	0.0075	0.00823	CcSEcCtD
Regadenoson—Vasodilation procedure—Epirubicin—liver cancer	0.0075	0.00823	CcSEcCtD
Regadenoson—Injection site pain—Doxorubicin—liver cancer	0.00747	0.0082	CcSEcCtD
Regadenoson—Angioedema—Sorafenib—liver cancer	0.00712	0.00782	CcSEcCtD
Regadenoson—Syncope—Sorafenib—liver cancer	0.00699	0.00767	CcSEcCtD
Regadenoson—Vasodilation procedure—Doxorubicin—liver cancer	0.00694	0.00762	CcSEcCtD
Regadenoson—Vasodilation—Doxorubicin—liver cancer	0.00694	0.00762	CcSEcCtD
Regadenoson—Loss of consciousness—Sorafenib—liver cancer	0.00685	0.00752	CcSEcCtD
Regadenoson—Cough—Sorafenib—liver cancer	0.0068	0.00747	CcSEcCtD
Regadenoson—Atrioventricular block—Epirubicin—liver cancer	0.00679	0.00746	CcSEcCtD
Regadenoson—Hypertension—Sorafenib—liver cancer	0.00673	0.00739	CcSEcCtD
Regadenoson—Musculoskeletal pain—Epirubicin—liver cancer	0.00667	0.00732	CcSEcCtD
Regadenoson—Arthralgia—Sorafenib—liver cancer	0.00664	0.00729	CcSEcCtD
Regadenoson—Myalgia—Sorafenib—liver cancer	0.00664	0.00729	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00659	0.00724	CcSEcCtD
Regadenoson—Anaphylactic shock—Sorafenib—liver cancer	0.00636	0.00698	CcSEcCtD
Regadenoson—Atrioventricular block—Doxorubicin—liver cancer	0.00629	0.0069	CcSEcCtD
Regadenoson—Shock—Sorafenib—liver cancer	0.00626	0.00687	CcSEcCtD
Regadenoson—Nervous system disorder—Sorafenib—liver cancer	0.00624	0.00685	CcSEcCtD
Regadenoson—Skin disorder—Sorafenib—liver cancer	0.00618	0.00678	CcSEcCtD
Regadenoson—Musculoskeletal pain—Doxorubicin—liver cancer	0.00617	0.00678	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0058	0.00636	CcSEcCtD
Regadenoson—Dyspnoea—Sorafenib—liver cancer	0.00567	0.00623	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Sorafenib—liver cancer	0.00549	0.00603	CcSEcCtD
Regadenoson—Pain—Sorafenib—liver cancer	0.00544	0.00597	CcSEcCtD
Regadenoson—Eye pain—Epirubicin—liver cancer	0.0053	0.00582	CcSEcCtD
Regadenoson—Gastrointestinal pain—Sorafenib—liver cancer	0.0052	0.00571	CcSEcCtD
Regadenoson—Urticaria—Sorafenib—liver cancer	0.00505	0.00555	CcSEcCtD
Regadenoson—Abdominal pain—Sorafenib—liver cancer	0.00503	0.00552	CcSEcCtD
Regadenoson—Renal impairment—Epirubicin—liver cancer	0.00503	0.00552	CcSEcCtD
Regadenoson—S-Adenosylmethionine—CYP2E1—liver cancer	0.00491	0.0551	CrCbGaD
Regadenoson—Eye pain—Doxorubicin—liver cancer	0.0049	0.00538	CcSEcCtD
Regadenoson—Cerebrovascular accident—Epirubicin—liver cancer	0.00488	0.00536	CcSEcCtD
Regadenoson—Pain in extremity—Epirubicin—liver cancer	0.00478	0.00525	CcSEcCtD
Regadenoson—Hypersensitivity—Sorafenib—liver cancer	0.00469	0.00515	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—liver cancer	0.00465	0.00511	CcSEcCtD
Regadenoson—Asthenia—Sorafenib—liver cancer	0.00456	0.00501	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—liver cancer	0.00455	0.00499	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—liver cancer	0.00452	0.00496	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—liver cancer	0.00443	0.00486	CcSEcCtD
Regadenoson—Diarrhoea—Sorafenib—liver cancer	0.00435	0.00478	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—liver cancer	0.00421	0.00462	CcSEcCtD
Regadenoson—Dizziness—Sorafenib—liver cancer	0.00421	0.00462	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—liver cancer	0.00416	0.00457	CcSEcCtD
Regadenoson—Asthma—Epirubicin—liver cancer	0.00413	0.00454	CcSEcCtD
Regadenoson—Vomiting—Sorafenib—liver cancer	0.00405	0.00444	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—liver cancer	0.00403	0.00442	CcSEcCtD
Regadenoson—Rash—Sorafenib—liver cancer	0.00401	0.0044	CcSEcCtD
Regadenoson—Dermatitis—Sorafenib—liver cancer	0.00401	0.0044	CcSEcCtD
Regadenoson—Headache—Sorafenib—liver cancer	0.00399	0.00438	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—liver cancer	0.00385	0.00423	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—liver cancer	0.00383	0.0042	CcSEcCtD
Regadenoson—Nausea—Sorafenib—liver cancer	0.00378	0.00415	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—liver cancer	0.00373	0.00409	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—liver cancer	0.00362	0.00398	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—liver cancer	0.00337	0.0037	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—liver cancer	0.00335	0.00368	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—liver cancer	0.00329	0.00362	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—liver cancer	0.00325	0.00357	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—liver cancer	0.00312	0.00342	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—liver cancer	0.00309	0.0034	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—liver cancer	0.00309	0.00339	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—liver cancer	0.00307	0.00337	CcSEcCtD
Regadenoson—Flushing—Epirubicin—liver cancer	0.00307	0.00337	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—liver cancer	0.00305	0.00334	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—liver cancer	0.00301	0.0033	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—liver cancer	0.003	0.0033	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—liver cancer	0.00299	0.00328	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—liver cancer	0.00298	0.00327	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—liver cancer	0.0029	0.00318	CcSEcCtD
Regadenoson—Erythema—Epirubicin—liver cancer	0.00288	0.00316	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—liver cancer	0.00286	0.00314	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—liver cancer	0.00285	0.00313	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—liver cancer	0.00284	0.00312	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—liver cancer	0.00284	0.00312	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—liver cancer	0.00282	0.0031	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—liver cancer	0.00278	0.00305	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—liver cancer	0.00277	0.00304	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—liver cancer	0.00276	0.00303	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—liver cancer	0.00272	0.00298	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—liver cancer	0.00268	0.00295	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—liver cancer	0.00267	0.00293	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—liver cancer	0.00267	0.00293	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—liver cancer	0.00261	0.00287	CcSEcCtD
Regadenoson—Malaise—Epirubicin—liver cancer	0.0026	0.00285	CcSEcCtD
Regadenoson—Syncope—Epirubicin—liver cancer	0.00258	0.00284	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—liver cancer	0.00255	0.0028	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—liver cancer	0.00253	0.00278	CcSEcCtD
Regadenoson—Cough—Epirubicin—liver cancer	0.00251	0.00276	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—liver cancer	0.00251	0.00276	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—liver cancer	0.0025	0.00274	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—liver cancer	0.00249	0.00273	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—liver cancer	0.00247	0.00272	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—liver cancer	0.00245	0.00269	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—liver cancer	0.00245	0.00269	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—liver cancer	0.00245	0.00269	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—liver cancer	0.00244	0.00268	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00244	0.00267	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—liver cancer	0.00242	0.00266	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—liver cancer	0.0024	0.00264	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—liver cancer	0.00239	0.00262	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—liver cancer	0.00236	0.00259	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—liver cancer	0.00235	0.00258	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—liver cancer	0.00234	0.00257	CcSEcCtD
Regadenoson—Cough—Doxorubicin—liver cancer	0.00233	0.00255	CcSEcCtD
Regadenoson—Shock—Epirubicin—liver cancer	0.00231	0.00254	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—liver cancer	0.00231	0.00254	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—liver cancer	0.00231	0.00253	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—liver cancer	0.0023	0.00253	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—liver cancer	0.00229	0.00252	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—liver cancer	0.00228	0.00251	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—liver cancer	0.00227	0.0025	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—liver cancer	0.00226	0.00248	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00225	0.00247	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—liver cancer	0.00224	0.00246	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—liver cancer	0.0022	0.00241	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—liver cancer	0.00218	0.00239	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Regadenoson—Shock—Doxorubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—liver cancer	0.00213	0.00234	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—liver cancer	0.00213	0.00233	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—liver cancer	0.00212	0.00233	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—liver cancer	0.00211	0.00232	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—liver cancer	0.00211	0.00232	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—liver cancer	0.0021	0.00231	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—liver cancer	0.0021	0.0023	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—liver cancer	0.00209	0.00229	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—liver cancer	0.00203	0.00223	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—liver cancer	0.00203	0.00223	CcSEcCtD
Regadenoson—Pain—Epirubicin—liver cancer	0.00201	0.00221	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00198	0.00218	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—liver cancer	0.00197	0.00216	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—liver cancer	0.00195	0.00214	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—liver cancer	0.00194	0.00213	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—liver cancer	0.00194	0.00213	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—liver cancer	0.00193	0.00212	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—liver cancer	0.00192	0.00211	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00188	0.00206	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—liver cancer	0.00187	0.00205	CcSEcCtD
Regadenoson—Pain—Doxorubicin—liver cancer	0.00186	0.00204	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—liver cancer	0.00186	0.00204	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—liver cancer	0.00179	0.00197	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—liver cancer	0.00178	0.00195	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—liver cancer	0.00173	0.0019	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—liver cancer	0.00173	0.0019	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—liver cancer	0.00172	0.00189	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—liver cancer	0.00169	0.00185	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—liver cancer	0.00161	0.00177	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—liver cancer	0.0016	0.00176	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—liver cancer	0.00156	0.00171	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—liver cancer	0.00155	0.00171	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—liver cancer	0.00149	0.00164	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—liver cancer	0.00149	0.00163	CcSEcCtD
Regadenoson—Rash—Epirubicin—liver cancer	0.00148	0.00163	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—liver cancer	0.00148	0.00163	CcSEcCtD
Regadenoson—Headache—Epirubicin—liver cancer	0.00147	0.00162	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—liver cancer	0.00144	0.00158	CcSEcCtD
Regadenoson—Nausea—Epirubicin—liver cancer	0.0014	0.00153	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—liver cancer	0.00138	0.00152	CcSEcCtD
Regadenoson—Rash—Doxorubicin—liver cancer	0.00137	0.00151	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—liver cancer	0.00137	0.0015	CcSEcCtD
Regadenoson—Headache—Doxorubicin—liver cancer	0.00136	0.0015	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—liver cancer	0.00129	0.00142	CcSEcCtD
